European Medicines Agency update on progressive multifocal leukoencephalopathy (PML) and Tysabri

View source ↗

Summary

EMA release updating on the risk of progressive multifocal leukoencephalopathy (PML) with natalizumab (Tysabri).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multifocal Leukoencephalopathy

Drugs mentioned

• Tysabri (Natalizumab)